Alzheimer's Disease and Advanced Drug Delivery Strategies

著者名：Prajapati PhD, Bhupendra G. (EDT)/Chellappan, Dinesh Kumar (EDT)/Kendre, Prakash (EDT)

Academic Press（2023/11/30発売）

• 言語：ENG
• ISBN：9780443132056
• eISBN：9780443132063

Description

Alzheimer's Disease and Advanced Drug Delivery Strategies compiles under a single volume the most recent advances in drug delivery to the brain as related to AD treatment.The editors recruited scientists from around the world to produce high quality chapters covering not only nanotechnological approaches, but also microsphere, niosomes, and liposomes. Among the topics covered are synthetic molecules, nobiletin, nose to brain delivery, natural biomaterials, cationic nanoformulations, dendrimers, microbubbles, and more.Alzheimer's Disease and Advanced Drug Delivery Strategies is a complete reference for academic and corporate pharma researchers investigating targeted drug delivery to the brain. Medical & Health Sciences researchers would also benefit from understanding the strategies compiled under this volume.- Provides insights into how advanced drug delivery systems can be effectively used for the management of Alzheimer's disease- Includes the most recent information on diagnostic methods and treatment strategies using controlled drug delivery systems- Covers recent perspectives and challenges towards the management and diagnosis of Alzheimer's Disease

Table of Contents

ContributorsAbout the editorsPreface Acknowledgments1. Etiology, pathogenesis of Alzheimer's disease and amyloid beta hypothesisSARIKA MARUTI KAMBLE, KALPESH RAMDAS PATIL AND AMAN B. UPAGANLAWAR1. Introduction 2. Etiology of Alzheimer's disease 3. Pathogenesis of Alzheimer's disease 4. Diagnosis of AD 5. Amyloid beta protein hypothesis 6. Consequences of amyloid beta (Ab) formation 7. Genetic factors responsible for the Alzheimer's disease References 2. Neuroinflammation in Alzheimer's diseaseMOHIT AGRAWAL, MANMOHAN SINGHAL, BHUPENDRA GOPALBHAI PRAJAPATI, HEMA CHAUDHARY, YASH JASORIA, BHAVNA KUMAR, MANDEEP KUMAR ARORA AND JAGANNATH SAHOO1. Introduction2. History of neuroinflammation in AD 3. The concept of neuroinflammation in AD 4. Neuroinflammation: Causes and consequences of Alzheimer's disease 5. BBB integrity and neuroinflammation 6. Role of cellular players 7. Role of mediators and modulators in neuroinflammation 8. Role of intracellular signaling pathway 9. Genetic studies 10. Imaging of neuroinflammation in AD 11. Possible intervention of neuroinflammation in AD 12. Factors associated with neuroinflammation 13. Development of therapeutic potential 14. Conclusion References 3. Recent updates in chemistry of Alzheimer's: Synthetic moleculesDEEPAK K. LOKWANI, SANGITA R. CHAVAN, VINOD G. UGALE, PRAKASH N. KENDRE AND SHIRISH P. JAIN1. Introduction2. MTDL approach associated with following scaffold or structures3. ConclusionReferences4. Blood brain barrier and its significance in drug delivery to brain in Alzheimer diseaseDHWANI RANA, SAGAR SALAVE, DIGNESH KHUNT AND DERAJRAM BENIVAL1. Introduction 2. Blood brain barrier 3. Current treatments for AD 4. Emerging therapies for AD 5. Nanotherapeutics for AD 6. Other approaches for crossing BBB 7. Conclusion and future perspective References5. Nose to brain delivery for the treatment of Alzheimer's diseaseDIGNESH KHUNT, SAGAR SALAVE, DHWANI RANA, DERAJRAM BENIVAL, BHAVIN GAYAKVAD AND BHUPENDRA GOPALBHAI PRAJAPATI1. Introduction 2. The nose-to-brain (N2B) pathway 3. AZD and current treament 4. Development of N2B delivery for AZD 5. Approaches to modulation of N2B delivery in AZD 6. Advantages of N2B delivery for AZD 7. Conclusion and future directions References 6. Amyloid cascade hypothesis, tau synthesis, and role of oxidative stress in ADJIGAR VYAS, NENSI RAYTTHATHA AND BHUPENDRA GOPALBHAI PRAJAPATI1. Introduction to the amyloid (amyloid-beta peptide) 2. Biogenesis of amyloid-beta 3. Amyloid cascade hypothesis (ACH) 4. Pros and cons of the ACH 5. Therapeutic targeting for amyloid-beta in Alzheimer's pathogenesis 6. Tau protein 7. Role of oxidative stress in AD 8. Corelation of amyloid B protein, tau process, and oxidative stress in AD References 7. New biologicals and biomaterials in the therapy of Alzheimer's diseaseVIPUL PRAJAPATI, SHRADDHA SHINDE, PRINCY SHRIVASTAV AND BHUPENDRA GOPALBHAI PRAJAPATI1. Introduction2. Potential target for Alzheimer's disease therapy3. Biologicals used in therapy of Alzheimer's disease4. Biomaterials used in therapy of Alzheimer's disease5. Nanoparticles in the therapy of Alzheimer's disease 6. Metal nanoparticles for Alzheimer's disease treatment7. Other NPs8. Systems based on biomaterials for mass production of therapeutic cells9. Challenges of biomaterial-based drug delivery approach in Alzheimer's disease10. ConclusionReferences8. Roles of nano medicine in diagnosis of Alzheimer's diseaseMONA AMIT KAUSHAL, NIKITA A. PATEL, GAURAVI XAVIER AND BHUPENDRA GOPALBHAI PRAJAPATI1. Introduction2. Diagnostic tools for AD3. Future perspective of nano medicine and their effectiveness4. Conclusion and limitationsReferences9. Nanotechnology-based delivery for CRISPR-Cas 9 cargo in Alzheimer's diseaseSHRUTI RAWAL, AKRUTI KHODAKIYA AND BHUPENDRA GOPALBHAI PRAJAPATI1. Introduction 2. Genome editing by CRISPR-Cas system3. Genome editing targets and scope of CRISPR-Cas 9 technology in Alzheimer's disease4.